Oslo, Norway, May 14, 2024 - Nykode Therapeutics ASA (OSE: NYKD), a
clinical-stage biopharmaceutical company dedicated to the discovery and
development of novel immunotherapies, today announced that it has expanded its
collaboration with MSD (Merck & Co., Inc., Rahway, NJ, USA) to include a
clinical trial collaboration and supply agreement for a phase 2 trial evaluating
Nykode's wholly-owned lead candidate, VB10.16, in combination with MSD's
anti-PD-1 therapy, KEYTRUDA® (pembrolizumab). This study will enroll
HPV16-positive high-risk patients with locally advanced cervical cancer
undergoing chemoradiotherapy. 

VB10.16 is a potentially first-in-class off-the-shelf therapeutic cancer vaccine
specifically designed to treat HPV16-induced malignancies. The cancer vaccine is
built on Nykode's technology platform of targeting antigens to antigen
presenting cells. Nykode has reported promising data from the phase 2 VB C-02
trial (NCT04405349) in heavily pre-treated cervical cancer patients receiving
VB10.16 in combination with atezolizumab with a median overall survival not yet
reached (estimated to 25 months at the time of analysis). These data support
Nykode's ongoing efforts with the phase 2 VB-C-04 trial (NCT06099418) in
second-line recurrent/metastatic cervical cancer. Furthermore, the VB10.16
clinical development program is expanding into new indications, including head
and neck cancer, for which Nykode has an existing clinical trial collaboration
and supply agreement with MSD for the ongoing VB-C-03 trial (NCT06016920)
evaluating VB10.16 in combination with KEYTRUDA in patients with HPV16-positive,
PD-L1-positive, recurrent or metastatic head and neck squamous cell carcinoma.

Agnete Fredriksen, EVP, Chief Scientific Officer and Business Development,
commented, "We are excited to expand our clinical development to include earlier
stages of cervical cancer where there is a significant unmet medical need, and
we see a huge potential for cancer vaccines. We are thrilled to continue
building on our already established, highly valued collaboration with the
experienced and talented team at MSD, a global leader in immuno-oncology."

KEYTRUDA® is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of
Merck & Co., Inc., Rahway, NJ, USA.


About Nykode Therapeutics
Nykode Therapeutics is a clinical-stage biopharmaceutical company dedicated to
the discovery and development of novel immunotherapies with a focus on the
treatment of cancer and autoimmune diseases. Nykode's modular vaccine technology
specifically targets antigens to antigen presenting cells (APC), which have been
shown to induce a broad, strong and long-lasting antigen specific immune
response in cancer, which correlates with clinical responses.

Nykode's lead product candidates are VB10.16, a therapeutic vaccine for the
treatment of HPV16 induced malignancies which demonstrated favorable safety and
efficacy results from its Phase 2 trial for the treatment of cervical cancer.
VB10.16 is being expanded into multiple trials for treatment of head and neck
cancer and cervical cancer. VB10.NEO, an individualized cancer neoantigen
vaccine, is exclusively out-licensed to Genentech, a member of the Roche Group. 

The Company's partnerships include Genentech within oncology and a multi-target
collaboration with Regeneron in oncology and infectious diseases.

Nykode is also utilizing its APC-targeted technology to create an inverse
vaccine platform for the potential use in autoimmune disorders, organ transplant
rejections, anti-drug antibody reactions and allergy.

Nykode Therapeutics' shares are traded on the Oslo Stock Exchange (OSE: NYKD).
Further information about Nykode Therapeutics can be found at
http://www.nykode.com.

Forward-looking statements for Nykode Therapeutics
This announcement and any materials distributed in connection with this
announcement may contain certain forward-looking statements. By their nature,
forward-looking statements involve risk and uncertainty because they reflect the
company's current expectations and assumptions as to future events and
circumstances that may not prove accurate. A number of material factors could
cause actual results and developments to differ materially from those expressed
or implied by these forward-looking statements.

Contact for Nykode Therapeutics ASA:
EVP, Chief Scientific Officer and Business Development, Agnete Fredriksen
Nykode Therapeutics ASA 
IR@nykode.com

Nykode Therapeutics ASA
Oslo Science Park
Gaustadalléen 21
N-0349 Oslo, Norway